NO20035597L - Forbedrede chelator-konjugater - Google Patents
Forbedrede chelator-konjugaterInfo
- Publication number
- NO20035597L NO20035597L NO20035597A NO20035597A NO20035597L NO 20035597 L NO20035597 L NO 20035597L NO 20035597 A NO20035597 A NO 20035597A NO 20035597 A NO20035597 A NO 20035597A NO 20035597 L NO20035597 L NO 20035597L
- Authority
- NO
- Norway
- Prior art keywords
- chelator conjugates
- improved
- improved chelator
- radiometal
- conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C251/36—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atoms of the oxyimino groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0116815.2A GB0116815D0 (en) | 2001-07-10 | 2001-07-10 | Improved chelator conjugates |
PCT/GB2002/003168 WO2003006070A2 (en) | 2001-07-10 | 2002-07-10 | Improved chelator conjugates |
Publications (3)
Publication Number | Publication Date |
---|---|
NO20035597D0 NO20035597D0 (no) | 2003-12-16 |
NO20035597L true NO20035597L (no) | 2004-03-03 |
NO334093B1 NO334093B1 (no) | 2013-12-09 |
Family
ID=9918227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20035597A NO334093B1 (no) | 2001-07-10 | 2003-12-16 | Forbedrede chelatdannerkonjugater, radioaktive metallkomplekser, radiofarmasøytika, sett for fremstilling av radiofarmasøytika, samt bifunksjonelle chelatdannere og fremgangsmåter for fremstilling av slike |
Country Status (21)
Country | Link |
---|---|
US (2) | US7597875B2 (no) |
EP (1) | EP1404377B1 (no) |
JP (1) | JP5015409B2 (no) |
KR (1) | KR100892009B1 (no) |
CN (4) | CN101538313A (no) |
AT (1) | ATE304866T1 (no) |
AU (1) | AU2002317317B2 (no) |
BR (1) | BR0210965A (no) |
CA (1) | CA2450690C (no) |
DE (1) | DE60206272T2 (no) |
DK (1) | DK1404377T3 (no) |
ES (1) | ES2250671T3 (no) |
GB (1) | GB0116815D0 (no) |
HK (1) | HK1064585A1 (no) |
HU (1) | HU228850B1 (no) |
IL (1) | IL159388A0 (no) |
MX (1) | MXPA04000210A (no) |
NO (1) | NO334093B1 (no) |
RU (1) | RU2298012C2 (no) |
WO (1) | WO2003006070A2 (no) |
ZA (1) | ZA200400143B (no) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002054088A2 (en) | 2001-01-05 | 2002-07-11 | Duke University | Contrast enhancement agent for magnetic resonance imaging |
NZ530156A (en) * | 2001-07-10 | 2007-04-27 | Ge Healthcare As | Peptide-based compounds for targeting integrin receptors for use as diagnostic imaging agents |
NO20030115D0 (no) | 2003-01-09 | 2003-01-09 | Amersham Health As | Kontrastmiddel |
GB0416062D0 (en) * | 2004-07-19 | 2004-08-18 | Amersham Plc | Improved N4 chelator conjugates |
US7785566B2 (en) | 2003-11-06 | 2010-08-31 | Ge Healthcare, Inc. | Pharmaceutical compounds |
WO2005049095A2 (en) | 2003-11-24 | 2005-06-02 | Amersham Health As | Contrast agent imaging angiotensin ii receptors |
DE602005017475D1 (de) * | 2004-03-04 | 2009-12-17 | Ge Healthcare As | Konjugate von angiotensin-peptid analoga und chelatbildner für diagnose und therapie |
RU2007118385A (ru) | 2004-11-22 | 2008-12-27 | Джи-И Хелткер АС (NO) | Контрастные агенты для направлений доставки во внеклеточный матрикс |
US20080226555A1 (en) * | 2005-06-08 | 2008-09-18 | Bengt Langstrom | Method for the Use of [11C] Carbon Monoxide in Labeling Synthesis of 11C-Labelled Esters and Acids by Sensitized Photo-Induced Free Radical |
GB0515974D0 (en) * | 2005-08-03 | 2005-09-07 | Ge Healthcare Ltd | Compounds and imaging methods |
ATE496881T1 (de) | 2006-02-15 | 2011-02-15 | Ge Healthcare As | Kontrastmittel |
US7943117B2 (en) * | 2006-06-08 | 2011-05-17 | Atomic Energy Council—Institute of Nuclear Research | Method for testing radiochemical purity of Tc-99m-TRODAT-1 |
ATE471724T1 (de) * | 2006-12-11 | 2010-07-15 | Ge Healthcare As | Radioaktiv markierte verbindungen auf peptidbasis und ihre verwendung |
AU2009322081C1 (en) * | 2008-12-02 | 2016-09-01 | Clarity Pharmaceuticals Ltd | Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals |
GB0922014D0 (en) | 2009-12-17 | 2010-02-03 | Ge Healthcare Ltd | Novel integrin binders |
HUE050033T2 (hu) | 2010-07-27 | 2020-11-30 | Serac Healthcare Ltd | Radioaktív gyógyszerkészítmények |
GB201103696D0 (en) * | 2011-03-04 | 2011-04-20 | Ge Healthcare Ltd | Technetium labelled peptides |
GB201110767D0 (en) | 2011-06-24 | 2011-08-10 | Ge Healthcare Ltd | Infection imaging |
US20130195756A1 (en) * | 2012-01-31 | 2013-08-01 | General Electric Company | 99mTc IMAGING AGENTS AND METHODS OF USE |
KR20150140650A (ko) * | 2013-02-15 | 2015-12-16 | 토마스 제퍼슨 유니버시티 | 종양 이미지를 위한 키트 |
GB201314936D0 (en) | 2013-08-21 | 2013-10-02 | Ge Healthcare Ltd | Radiolabelling method |
GB201322456D0 (en) | 2013-12-18 | 2014-02-05 | Ge Healthcare Ltd | Radiotracer compositions and methods |
US11033642B2 (en) | 2014-03-19 | 2021-06-15 | Universitat Zurich | Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy |
WO2019217571A1 (en) * | 2018-05-08 | 2019-11-14 | University Of Miami | Materials and methods for the delivery of therapeutic nucleic acids to tissues |
WO2019222454A1 (en) | 2018-05-16 | 2019-11-21 | Emory University | Styrylbenzothiazole derivatives and uses in imaging |
CN111548275A (zh) * | 2020-05-27 | 2020-08-18 | 龙曦宁(上海)医药科技有限公司 | 一种2-(氨基甲基)-n1,n1-二甲基丙烷-1,3-二胺三盐酸盐的合成方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1588978A (en) * | 1977-07-19 | 1981-05-07 | Ici Ltd | Coating processes |
DE3930674A1 (de) * | 1989-09-11 | 1991-03-21 | Diagnostikforschung Inst | Bifunktionelle chelatbildner zur komplexierung von tc- und re-isotopen, verfahren zu ihrer herstellung und darstellung von konjugaten daraus sowie deren verwendung in diagnostik und therapie |
US5808091A (en) * | 1991-10-29 | 1998-09-15 | Bracco International B.V. | Rhenium and technetium complexes containing a hypoxia localizing moiety |
JP3083157B2 (ja) * | 1993-08-04 | 2000-09-04 | アマーシャム・インターナショナル・ピーエルシー | 酸素欠乏性組織に局在する放射性金属錯体 |
KR960700986A (ko) * | 1994-01-12 | 1996-02-24 | 네나드 토모브-그리소고노 | 리간드 및 이들의 금속착체(ligands and metal complexes thereof) |
CA2179990A1 (en) * | 1994-01-12 | 1995-07-20 | Gary Robert Bower | Biological targeting agents |
WO1999060018A1 (en) * | 1998-05-15 | 1999-11-25 | Nycomed Amersham Plc | Labelled glutamine and lysine analogues |
US6783711B2 (en) * | 2000-05-23 | 2004-08-31 | Ge Osmonics, Inc. | Process for preparing a sulfonamide polymer matrix |
WO2002072718A1 (fr) * | 2001-03-08 | 2002-09-19 | Matsushita Electric Industrial Co., Ltd. | Encre d'impression a jet d'encre, procede de production de l'encre, cartouche d'encre et dispositif d'impression comportant cette encre |
-
2001
- 2001-07-10 GB GBGB0116815.2A patent/GB0116815D0/en not_active Ceased
-
2002
- 2002-07-08 CN CNA2008102133680A patent/CN101538313A/zh active Pending
- 2002-07-08 CN CNA200910127855XA patent/CN101537190A/zh active Pending
- 2002-07-10 EP EP02745600A patent/EP1404377B1/en not_active Expired - Lifetime
- 2002-07-10 DE DE60206272T patent/DE60206272T2/de not_active Expired - Lifetime
- 2002-07-10 CA CA002450690A patent/CA2450690C/en not_active Expired - Lifetime
- 2002-07-10 IL IL15938802A patent/IL159388A0/xx unknown
- 2002-07-10 HU HU0401265A patent/HU228850B1/hu not_active IP Right Cessation
- 2002-07-10 AU AU2002317317A patent/AU2002317317B2/en not_active Ceased
- 2002-07-10 DK DK02745600T patent/DK1404377T3/da active
- 2002-07-10 KR KR1020047000303A patent/KR100892009B1/ko not_active IP Right Cessation
- 2002-07-10 MX MXPA04000210A patent/MXPA04000210A/es active IP Right Grant
- 2002-07-10 ES ES02745600T patent/ES2250671T3/es not_active Expired - Lifetime
- 2002-07-10 US US10/483,455 patent/US7597875B2/en not_active Expired - Lifetime
- 2002-07-10 RU RU2003137592/04A patent/RU2298012C2/ru not_active IP Right Cessation
- 2002-07-10 AT AT02745600T patent/ATE304866T1/de active
- 2002-07-10 JP JP2003511875A patent/JP5015409B2/ja not_active Expired - Lifetime
- 2002-07-10 CN CNB028140087A patent/CN100509061C/zh not_active Expired - Fee Related
- 2002-07-10 WO PCT/GB2002/003168 patent/WO2003006070A2/en active IP Right Grant
- 2002-07-10 CN CN2009102035216A patent/CN101607913B/zh not_active Expired - Fee Related
- 2002-07-10 BR BR0210965-4A patent/BR0210965A/pt active Pending
-
2003
- 2003-12-16 NO NO20035597A patent/NO334093B1/no not_active IP Right Cessation
-
2004
- 2004-01-08 ZA ZA200400143A patent/ZA200400143B/xx unknown
- 2004-09-22 HK HK04107295A patent/HK1064585A1/xx not_active IP Right Cessation
-
2009
- 2009-10-01 US US12/571,508 patent/US8852550B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1404377T3 (da) | Forbedrede chelatorkonjugater | |
MA30153B1 (fr) | Anticorps anti-ox40l et methodes correspondantes | |
DK1791571T3 (da) | Radiofluorinerede peptider | |
DE60230890D1 (de) | Indolizine als kinaseproteinhemmer | |
RS50660B (sr) | Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže | |
MXPA05009682A (es) | Metodos de radiofluorinacion de vectores biologicamente activos. | |
BRPI0411897A (pt) | pirroldihidroisoquinolinas como inibidores de pde10 | |
ECSP034600A (es) | Compuestos de lactama | |
CL2013002895A1 (es) | Compuestos derivados de 7,8-dihidro-5h-pteridin-6-ona, utiles como intermediarios en la sintesis de compuestos derivados de pteridinona (divisional de la solicitud 3123-2005). | |
BRPI0307702B8 (pt) | formulações de solução contendo anticorpo | |
MA30042B1 (fr) | Composes calcilytiques | |
WO2003104425A3 (en) | NEW STABLE ANTI-CD22 ANTIBODIES | |
DE60210598D1 (de) | 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA | |
DE60322562D1 (de) | Konjugate von tc komplexen und zielgerichtete einheiten und ihre verwendung in nmr-diagnostik | |
TR199901017A2 (xx) | B�cek ilac� terkibi. | |
DE60213084D1 (de) | 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA | |
RS20060195A (en) | Imidazopyridine-derivatives as inducible no-synthase inhibitors | |
ATE242763T1 (de) | Methoximinophenylessigsäureamide | |
EA200400393A1 (ru) | Антитела против каспазы-8, их получение и применение | |
ITMI20030827A1 (it) | Composizione farmaceutica contenente l'associazione levodopa/carbidopa. | |
NO20021429L (no) | 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner | |
EA200400764A1 (ru) | 1,3-диарилпроп-2-ен-1-оны, композиция на их основе и применение | |
ES2183543T3 (es) | Derivado de tiocolchicosida, su preparacion y su aplicacion en terapeutica. | |
HN1999000157A (es) | 1,2,3 tetrahidroquinolinas 2 - sustituidas 4 - amino sustituidas. | |
UA115859C2 (uk) | Розчинний поліпептид, який зв'язує активін а, та композиція, що його містить |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |